{"id":962059,"date":"2026-05-13T07:34:21","date_gmt":"2026-05-13T11:34:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/"},"modified":"2026-05-13T07:34:21","modified_gmt":"2026-05-13T11:34:21","slug":"briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/","title":{"rendered":"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong><br \/>\n            <em>Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners<\/em><br \/>\n          <\/strong><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">PHILADELPHIA and VANCOUVER, British Columbia, May  13, 2026  (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of Penn Medicine\u2019s Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell\u2019s ongoing pivotal Phase 3 clinical study (Bria-ABC).<\/p>\n<p align=\"justify\">BriaCell has received increased interest from leading cancer centers and continued enrollment momentum following the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CgT0Pue-dFD-nJJreyKOBlgg2l8qfn4QoeVBfOKg3OFUVUEUlA-UQGW1JJ19o6A8W5AymkDcOOELN3B4xKSgGrxBImU5wh6EkdZT0eRYgacYV9YPXOzonbL0zrDr5MDSK0l3hhXq7N63jyqRC-9s_CMzS5LHXx0XJs4xqpEwO4yGePbH_HonL-Vfksvc0zRl\" rel=\"nofollow\" target=\"_blank\">independent inclusion<\/a> of its Phase 3 clinical trial in <em>Nature Medicine\u2019s <\/em>article, \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7-T05QOWFaMySrICnSDp796QGx1yN94o_mmNLYov_iyJUEbVvfA9YQj3jmKcvrQbYj4kgGkaHuIatS1W24ceNA6Btvd1xwp2uE4SEhV9dOL-w-jQvpGuWjefPABW4LhbIRvJJBvuLQUd_PQVjPLfe5tGe_XrI9WllgJY4Zx2jZ_MByzuNAvEB6p2nGYWbTAu\" rel=\"nofollow\" target=\"_blank\"><em>Eleven clinical trials that will shape medicine in 2026<\/em><\/a>\u201d. The Phase 3 Bria-ABC study is evaluating BriaCell\u2019s lead clinical candidate, Bria-IMT\u2122, in combination with an immune checkpoint inhibitor versus physician\u2019s choice of treatment in\u00a0<u>a<\/u>dvanced\u00a0<u>b<\/u>reast\u00a0<u>c<\/u>ancer.<\/p>\n<p align=\"justify\">\u201cWe are pleased to partner with Penn Medicine\u2019s Abramson Cancer Center, a world-renowned cancer institute, as a clinical site in BriaCell\u2019s Phase 3 study,\u201d stated Dr. William V. Williams, BriaCell\u2019s President &amp; CEO. \u201cWe look forward to working with the cancer experts at Penn to offer the Bria-IMT regimen to patients with metastatic breast cancer with the goal of making a meaningful difference for patients who have not responded to prior therapies.\u201d<\/p>\n<p align=\"justify\">\u201cThe addition of Penn Medicine\u2019s Abramson Cancer Center supports our goal of expanding access to BriaCell\u2019s novel immunotherapy regimen to patients with metastatic breast cancer across the greater Philadelphia region,\u201d said Dr. Giuseppe Del Priore, BriaCell\u2019s Chief Medical Officer.<\/p>\n<p align=\"justify\">Other recently activated sites include:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left\">Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN<\/li>\n<li style=\"text-align:left\">University of Virginia (UVA) Comprehensive Cancer Center, Charlottesville, VA<\/li>\n<li style=\"text-align:left\">Baptist Health South Florida, Coral Gables, FL<\/li>\n<li style=\"text-align:left\">SCRI Oncology Partners, Nashville, TN\n<\/li>\n<\/ul>\n<p align=\"justify\">An interim analysis of the pivotal Phase 3 study will be conducted after 144 patient events, defined as deaths, have occurred. Overall survival (OS) is the primary endpoint. The study compares the Bria-IMT regimen in combination with an immune checkpoint inhibitor versus physician\u2019s choice of treatment in patients with advanced metastatic breast cancer. The Bria-IMT combination regimen has received FDA Fast Track designation, reflecting its potential to address a serious unmet medical need.<\/p>\n<p align=\"justify\">For additional information on BriaCell\u2019s pivotal Phase 3 study, please visit ClinicalTrials.gov\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gf7skdmjlo-XKBhn7i6sVORsoX1c5RUhAcreM6ZpKqjd0CWwD2-avNzLU2Dfqrj9XbC7pD1ka9KKcE3Gbc_LW7LN36O4tNSFuqu8TQ-79x72FdcioWYgICTa8jJBJqvD\" rel=\"nofollow\" target=\"_blank\">NCT06072612<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About BriaCell Therapeutics Corp.<\/strong>\n      <\/p>\n<p align=\"justify\">BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ntQ_YQyVpiePxSB1pHfJ4_29_ohxKUeKsxBE_8-9XFa0kSWPO3Lgwkte6tY2vfbL9AhMOI7-3NsDvI1G0LlZWVI6Nk6cbYH_UTtQSny-LY0=\" rel=\"nofollow\" target=\"_blank\">https:\/\/briacell.com\/<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains \u201cforward-looking statements\u201d that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cseek,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201ctarget,\u201d \u201caim,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the addition of a new clinical site in the ongoing pivotal Phase 3 clinical study of Bria\u2011IMT, and expectations regarding patient enrollment, interim analysis timing and the potential clinical benefits of the Bria\u2011IMT combination regimen, are based on BriaCell\u2019s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading \u201cRisks and Uncertainties\u201d in the Company\u2019s most recent Management\u2019s Discussion and Analysis, under the heading \u201cRisk Factors\u201d in the Company\u2019s most recent Annual Information Form, and under \u201cRisks and Uncertainties\u201d in the Company\u2019s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company&#8217;s profiles on SEDAR+ at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-0LzYPcdaSt6gFrY3593a3soxn8zRycfMPr0fwlbsquUrbQHeR6Czqq8bS3FxBUnOIaBiI05pn91uu3Q9nkPZ-UF_T4trb6o4kpU9krHWzIEZ5CE3cfkJy1Dd-QU3Dhajtgbwhfv4BJZ87sqaxSgSocxC6eoSp23Q1y3CT8OVjm3Ms6D-SynIE59Fwa4kCTVp8iJsFGgUX5Mjrem3yd3nhop1a-4GtKU55QOiuSGl0vbN-eY7le9_0dMrePUQa9HIDOYnipVH-RcRTZA-_h_aw==\" rel=\"nofollow\" target=\"_blank\"><strong>www.sedarplus.ca\u00a0<\/strong><\/a>and on EDGAR at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-0LzYPcdaSt6gFrY3593a703u3CuEYWA4HR3ou-9xzerz99iIuRkYk4Q91zOmIhL93blga20Zok5IJkXuBZHjJa5pFklDRCyGnPDZvxlgdWcvzo4CTeCj0C1LaGxCuayfTlNonCWS68FSH2iDG3Ds-b5Tny1mm81csz8JvWIFtwUXqkKtEy0jC980Lf2IJr4CiBo8R7VKyMDFbHQ6qa_vefvvKRmN2FIFJF5llH04cs=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.<\/p>\n<p align=\"justify\">Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.<\/p>\n<p align=\"justify\">\n        <strong>Contact Information<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>William V. Williams, MD<br \/>President &amp; CEO<br \/>1-888-485-6340<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=A_xGd6QKl0JVQz-rblnuTKjXX2W5mAqNXJhR1l0Si3aCcrv6nS93rB7VV_qgfiZ7QuY6pRTXxuKYllmhyRBJfvuWQfbIof_CBoYzW6OEcSJvaSJ_PnlmqMjLjoS59cjTXwPQERmSrIGNws5Xfh0FOBRwsKwDGtRy0f9zAA2kn4-RjWPIhsBwasbKoWr50MHOtwB-HEGprby6glo5BAmlLcICXAOE0wtBrSZJUdfo97x-H1shU0IFGoisQWNlUyjM7HZMtCkvqxmOMxc73880yA==\" rel=\"nofollow\" target=\"_blank\">info@briacell.com<\/a><\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jH_9QcXaPYkUDThTKl846yShrMWFHntU9nHKnj9A0GQWZotYjKYU8aVnMncdVrHfSpRv2DMTodBv3WHpGvgfxTkX5h6EJw_p3w8c6u2d6_bWrAgOeTisPOdzmL4I-xA0Q0QI5t0nALwds9Ul9ih5uXvh-4Ioyy23evt3WlloxAGCS091g7f6bVhqzraN67B4cseVKqZfCOrvezzFE_hIugv6ngd2FqIooEkNx14HcPQZ8gKz0LC55uy3yDGVJJd6zfB9sDF63uSk9tBFZIzIlw==\" rel=\"nofollow\" target=\"_blank\">investors@briacell.com<\/a>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NzdlZTZhNjItYjlmMS00YWQ2LTgwNmItMDk0ZjY3Y2M0ZTZhLTExMDIyMjktMjAyNi0wNS0xMy1lbg==\/tiny\/BriaCell-Therapeutics-Corp-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of Penn Medicine\u2019s Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell\u2019s ongoing pivotal Phase 3 clinical study (Bria-ABC). BriaCell has received increased interest from leading cancer centers and continued enrollment momentum following the independent inclusion of its Phase 3 clinical trial in Nature Medicine\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962059","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of Penn Medicine\u2019s Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell\u2019s ongoing pivotal Phase 3 clinical study (Bria-ABC). BriaCell has received increased interest from leading cancer centers and continued enrollment momentum following the independent inclusion of its Phase 3 clinical trial in Nature Medicine\u2019s &hellip; Continue reading &quot;BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T11:34:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study\",\"datePublished\":\"2026-05-13T11:34:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/\"},\"wordCount\":781,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/\",\"name\":\"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=\",\"datePublished\":\"2026-05-13T11:34:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/","og_locale":"en_US","og_type":"article","og_title":"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Market Newsdesk","og_description":"Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners PHILADELPHIA and VANCOUVER, British Columbia, May 13, 2026 (GLOBE NEWSWIRE) &#8212; BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (\u201cBriaCell\u201d or the \u201cCompany\u201d), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of Penn Medicine\u2019s Abramson Cancer Center, an internationally recognized cancer center, as a clinical trial site in BriaCell\u2019s ongoing pivotal Phase 3 clinical study (Bria-ABC). BriaCell has received increased interest from leading cancer centers and continued enrollment momentum following the independent inclusion of its Phase 3 clinical trial in Nature Medicine\u2019s &hellip; Continue reading \"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T11:34:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study","datePublished":"2026-05-13T11:34:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/"},"wordCount":781,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/","name":"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=","datePublished":"2026-05-13T11:34:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxOTAxMCM3NTk5ODU1IzIwOTA2NTg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/briacell-adds-penn-medicines-abramson-cancer-center-as-clinical-site-in-pivotal-phase-3-breast-cancer-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BriaCell Adds Penn Medicine\u2019s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962059"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962059\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}